Company Monitoring Page for Roche

latest headlines for company on cafepharma

Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Endpoints
Tue, 01/14/20 - 10:20 am
Tags:
SMA, Roche, risdiplam, Biogen, Novartis, drug pricing
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
Mon, 01/13/20 - 11:35 pm
Tags:
stem cells, MS, multiple sclerosis, NIH, AHSCT, Biogen, Tysabri, Sanofi, Lemtrada, Roche, Ocrevus, Rituxan
Roche Pays $40M to Use Amunix Pharma’s Half-Life Extension Tech
Xconomy
Mon, 01/13/20 - 10:49 am
Tags:
Roche, Amunix, R&D, half-life extension, XTEN
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Endpoints
Fri, 01/10/20 - 10:21 am
Tags:
Roche, immuno-oncology, Amunix, Merck, CAR-T
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Fierce Pharma
Sat, 01/4/20 - 07:31 pm
Tags:
Roche, Tecentriq, NICE, UK, Small-Cell Lung Cancer
Top Biopharma M&As in 2019
BioSpace
Fri, 01/3/20 - 10:06 am
Tags:
M&A, Bristol-Myers Squibb, Celgene, AbbVie, Allergan, Roche, Spark Therapeutics, Novartis, The Medicines Company, Alkermes, Rodin Therapeutics, Sumitomo Dainippon, Roivant
An immuno-oncology triplet from Roche shows promise in mouse models of several tumors
Fierce Biotech
Fri, 01/3/20 - 09:44 am
Tags:
Roche, targeted antibodies, breast cancer, colon cancer, skin cancer
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Tue, 12/24/19 - 12:00 am
Tags:
Roche, Sarepta Therapeutics, FDA, Duchenne Muscular Dystrophy, SRP-9001
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Fri, 12/20/19 - 12:15 pm
Tags:
Amgen, Allergan, biosimilar, Roche, Rituxan
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Fierce Pharma
Thu, 12/19/19 - 11:06 pm
Tags:
drug ads, television ads, Roche, Ocrevus, GSK, Dovato, AbbVie, Humira
WHO Prequalifies its First Biosimilar
RAPS.org
Thu, 12/19/19 - 06:01 pm
Tags:
WHO, biosimilars, Samsung Bioepis, Ontruzant, Roche, Herceptin, breast cancer
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
BioSpace
Thu, 12/19/19 - 12:45 pm
Tags:
Roche, Genentech, Arcus Biosciences, clinical trials, colorectal cancer, pancreatic cancer, AB928
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
Tue, 12/17/19 - 09:29 pm
Tags:
ESMO, Roche, Tecentriq, non-small cell lung cancer
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Tue, 12/17/19 - 10:34 am
Tags:
Novartis, Europe, GSK, Sanofi, AstraZeneca, Roche
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Mon, 12/16/19 - 10:46 pm
Tags:
Roche, Spark Therapeutics, M&A, FTC
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Pharmaforum
Mon, 12/16/19 - 10:46 am
Tags:
Spark Therapeutics, Roche, UK, M&A, CMA
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Fri, 12/13/19 - 12:20 pm
Tags:
Roche, Perjeta, Herceptin, HER2+ breast cancer, SABCS, breast cancer
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
Fierce Pharma
Thu, 12/12/19 - 11:12 am
Tags:
Merck, Ketyruda, Roche, Tecentriq, immuno-oncology, SABCS, triple-negative breast cancer
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Wed, 12/11/19 - 10:35 am
Tags:
Roche, breast cancer, Herceptin, Perjeta, biosimilars, SABCS
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Mon, 12/9/19 - 11:42 pm
Tags:
Roche, Spark Therapeutics, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.